• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Medical methods for first trimester abortion
CONCLUSIONS: Safe and effective medical abortion methods are available. Combined regimens (prostaglandin combined with mifepristone, letrozole, estradiol valerate, tamoxifen, or methotrexate) may be more effective than single agents (prostaglandin alone or mifepristone alone). In the combined regimen, the dose of mifepristone can probably be lowered to 200 mg without significantly decreasing effectiveness. Vaginal misoprostol is probably more effective than oral administration, and may have fewer side effects than sublingual or buccal. Some results are limited by the small numbers of participants on which they are based. A...
Source: Cochrane Database of Systematic Reviews - May 24, 2022 Category: General Medicine Authors: Jing Zhang Kunyan Zhou Dan Shan Xiaoyan Luo Source Type: research

Traditional Korean medicine treatment for tamoxifen associated adverse events of breast cancer patient: A CARE - Compliant case report
CONCLUSION: This case report suggests that traditional Korean medicine interventions might have improved the adverse events of tamoxifen in breast cancer patients.PMID:33845285 | DOI:10.1016/j.ctcp.2021.101378
Source: Clinical Genitourinary Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Jihye Seo Donghun Lee Hee-Geun Jo Source Type: research

Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
CONCLUSIONS: This review found evidence that supports adding OFS for premenopausal women with early, hormone receptor-positive breast cancers. The benefit of OFS persisted when compared to observation, and when added to endocrine therapy (tamoxifen) or chemotherapy and endocrine therapy (tamoxifen). The decision to use OFS may depend on the overall risk assessment based on tumour and patient characteristics, and may follow consideration of all side effects that occur with the addition of OFS. PMID: 32141074 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - March 5, 2020 Category: General Medicine Authors: Bui KT, Willson ML, Goel S, Beith J, Goodwin A Tags: Cochrane Database Syst Rev Source Type: research

Risk-reducing medications for primary breast cancer: a network meta-analysis.
CONCLUSIONS: For women with an above-average risk of developing breast cancer, CPAs can reduce the incidence of this disease. AIs appear to be more effective than SERMs (tamoxifen) in reducing the risk of developing breast cancer. AIs are not associated with an increased risk of endometrial cancer and thromboembolic events. However, long-term data on toxicities from tamoxifen are available while the follow-up toxicity data on unaffected women taking AIs is relatively short. Additional data from direct comparisons are needed to fully address the issues of breast cancer prevention by risk-reducing medications, with special r...
Source: Cochrane Database of Systematic Reviews - April 28, 2019 Category: General Medicine Authors: Mocellin S, Goodwin A, Pasquali S Tags: Cochrane Database Syst Rev Source Type: research

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
CONCLUSIONS: The LNG-IUS reduces the incidence of benign endometrial polyps and endometrial hyperplasia in women with breast cancer taking tamoxifen. At 12 and 24 months of follow-up, the LNG-IUS increased abnormal vaginal bleeding or spotting among women in the treatment group compared to those in the control. There is no clear evidence from the available randomised controlled trials that the LNG-IUS prevents endometrial cancer in these women. There is no clear evidence from the available randomised controlled trials that the LNG-IUS affects the risk of breast cancer recurrence or breast cancer-related deaths. Larger stud...
Source: Cochrane Database of Systematic Reviews - December 9, 2015 Category: Journals (General) Authors: Dominick S, Hickey M, Chin J, Su HI Tags: Cochrane Database Syst Rev Source Type: research

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
CONCLUSIONS: Primary endocrine therapy should only be offered to women with oestrogen receptor (ER)-positive tumours who are unfit for surgery, at increased risk of serious surgical or anaesthetic complications if subjected to surgery, or who refuse surgery. In a cohort of women with significant co-morbid disease and ER-positive tumours it is possible that primary endocrine therapy may be a superior option to surgery. Trials are needed to evaluate the clinical effectiveness of aromatase inhibitors as primary therapy for an infirm older population with ER-positive tumours. PMID: 24838672 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 16, 2014 Category: Journals (General) Authors: Morgan J, Wyld L, Collins KA, Reed MW Tags: Cochrane Database Syst Rev Source Type: research

Post-operative radiotherapy for ductal carcinoma in situ of the breast.
CONCLUSIONS: This review confirms the benefit of adding radiotherapy to breast conserving surgery for the treatment of all women diagnosed with DCIS. No long-term toxicity from use of radiotherapy was identified. PMID: 24259251 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - November 21, 2013 Category: Journals (General) Authors: Goodwin A, Parker S, Ghersi D, Wilcken N Tags: Cochrane Database Syst Rev Source Type: research